Literature DB >> 18466093

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.

Andri Rauch1, David Nolan, Hansjakob Furrer, Elizabeth McKinnon, Mina John, Simon Mallal, Silvana Gaudieri, Huldrych F Günthard, Patrick Schmid, Manuel Battegay, Bernard Hirschel, Amalio Telenti, Ian James.   

Abstract

We assessed the influence of human leukocyte antigen (HLA) alleles HLA-Bw4 and HLA-Bw6 on CD4 T cell recovery after starting successful combination antiretroviral therapy in 265 individuals. The median gains in the CD4 T cell count after 4 years were 258 cells/microL for HLA-Bw4 homozygotes, 321 cells/microL for HLA-Bw4/Bw6 heterozygotes, and 363 cells/microL for HLA-Bw6 homozygotes (P = .01, compared with HLA-Bw4 homozygotes). HLA-Bw4 homozygosity appears to predict an impaired CD4 T cell recovery after initiation of combination antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18466093     DOI： 10.1086/588479

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

1.  Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy.

Authors:  Mark H Kuniholm; Xiaojiang Gao; Xiaonan Xue; Andrea Kovacs; Kathryn Anastos; Darlene Marti; Ruth M Greenblatt; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Melissa Fazzari; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

2.  Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responses.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2009-11-05       Impact factor: 2.850

3.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

4.  Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.

Authors:  Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

5.  T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384.

Authors:  Todd Hulgan; Gregory K Robbins; Spyros A Kalams; David C Samuels; Benjamin Grady; Robert Shafer; Deborah G Murdock; Doug Selph; David W Haas; Richard B Pollard
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

6.  Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.

Authors:  Raghavan Sampathkumar; Elnaz Shadabi; Ma Luo
Journal:  Adv Virol       Date:  2012-05-16

7.  KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy.

Authors:  Alessandro Soria; Franca Rosa Guerini; Alessandra Bandera; Elisabetta Bolognesi; Alessia Uglietti; Caterina Fusco; Patrizia Zucchi; Renato Maserati; Giuliano Rizzardini; Mario Clerici; Andrea Gori
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

8.  The influence of HLA on HIV-associated neurocognitive impairment in Anhui, China.

Authors:  Rachel D Schrier; Saurabh Gupta; Patricia Riggs; Lucette A Cysique; Scott Letendre; Hua Jin; Stephen A Spector; Kumud K Singh; Tanya Wolfson; Zunyou Wu; Kun Xue Hong; Xin Yu; Chuan Shi; Robert K Heaton
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

9.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

10.  Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).

Authors:  Leona Dold; Golo Ahlenstiel; Eva Althausen; Carolin Luda; Carolynne Schwarze-Zander; Christoph Boesecke; Jan-Christian Wasmuth; Jürgen Kurt Rockstroh; Ulrich Spengler
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.